key: cord-1046105-uc1fjl40 authors: Chumbita, Mariana; Puerta-Alcalde, Pedro; Garcia-Pouton, Nicole; García-Vidal, Carolina title: COVID-19 and fungal infections: Etiopathogenesis and therapeutic implications date: 2021-09-30 journal: Rev Esp Quimioter DOI: 10.37201/req/s01.21.2021 sha: 8f61ba29084e1a66a6ce4304be89f258e0979ec4 doc_id: 1046105 cord_uid: uc1fjl40 Invasive fungal infection often complicates patients with severe viral infection, especially those admitted to critical care units. Severe SARS-CoV-2 infection has been no exception and a significant association with Aspergillus spp. has been documented, resulting in high patient mortality. In this summary we describe the clinical presentation, the underlying diseases most commonly linked with this association, radiological manifestations and therapeutic management of CAPA. The relationship between invasive aspergillosis (IA) and viral infection, mainly influenza A, in critically ill patients with acute respiratory distress syndrome (ARDS) is widely known nowadays. Since 1972, when this association was first published [1] , this association had hardly been described. However, in 2011, and following the remarkable advancements made in diagnostic techniques for influenza infection-that is, a real-time polymerase chain reaction (PCR) performed on nasopharyngeal throat swabs-and invasive aspergillosis, the role of invasive pulmonary aspergillosis (IPA) complicating severe influenza became more evident. Indeed, several publications demonstrated a strong association between the two diseases [2, 3] . In one particular paper, investigators developed the AspICU algorithm [4] to define IPA in critical care patients with viral infections. One of the most important publications in this field detailed the relationship between viral infections and Aspergillus mainly due to bronchoalveolar lavage (BAL). This data suggests that these patients were in advanced stages of the disease with the presence of angioinvasion. Also, described mortality rates (52.2%) were higher. Due to the importance of this entity, a group of 22 experts from six continents and 14 countries gathered together to develop guidelines for the management, diagnosis and treatment of CAPA [10] . In this review, they proposed three clinical forms: i) proven aspergillosis when invasive growth of Aspergillus was evidenced in histopathological and/or microbiological samples obtained from a sterile tissue; ii) probable aspergillosis when Aspergillus spp. evidence was obtained from BAL or blood (culture, GM, or Aspergillus PCR); iii) possible aspergillosis when compatible radiological findings were described together with mycological evidence obtained via non-bronchoscopic lavage. In conclusion, should clinical findings elicit suspicion and meet inclusion criteria, it is necessary to initiate diagnostic tests for CAPA, so as to avoid a rapid and undesirable evolution towards more invasive forms. As high mortality has been reported in cases of CAPA, [11, 12] early and adequate therapy is crucial. Traditionally, voriconazole or isavuconazole has AI evidence for the treat-predominantly prior lung disease that required ICU admission with respiratory support for more than nine days. Third, performing cultures of respiratory samples, mainly tracheal aspirates, was the most common diagnostic testing approach. In the study by Marr et al. [8] , only 25% of serum galactomannan (GM) was positive among patients with CA-PA. Conversely, because of invasive diagnostic strategies used in both centers and the lower rate of angioinvasion, 17 of 20 (85%) respiratory cultures tested positive. This observance may be attributable to the fact that these patients were in early stages of the disease. In this series, mortality rates were relatively low. Furthermore, Salmanton-Garcia et al. [9] reported 186 cases of CAPA across 17 different countries collected from Fungiscope (a global emerging fungal infection registry; https://www.clinicaltrials.gov;National Clinical Trial identifier NCT01731353) and a literature search. In this large series, we found again that 97.8% of patients were admitted to the ICU, and 94.1% required mechanical ventilation. Investigators observed median days until CAPA diagnosis of 10, which was similar to data reported in the multicentric series by Marr et al. [8] . A notable difference between both studies is that up to 60.8% of total CAPA were diagnosed with a positive GM, Quarterly timeline about cases reported for coronavirus disease-associated pulmonary aspergillosis. ment of IA in main guidelines [13] . However, both drugs are quite different. Table 1 summarizes potential advantages with the use of isavuconazole. Remarkably, isavuconazole has fewer interactions than voriconazole. This fact is of main interest in patients with COVID-19, especially in those who require ICU admission. Baniasadi et al. [14] reported data from a prospective study about drug-drug interactions among patients in ICU, and voriconazole was one of the more frequently involved drugs due to its ability to inhibit CYP3A4 [15] . Secondarily, voriconazole interacts with corticosteroids, some sedative drugs and remdesivir. Isavuconazole is metabolized differently via CYP2C19, CYP2C9, and CYP3A4, which makes the possibility of drug-drug interaction significantly lower. The use of voriconazole must therefore be associated with therapeutic drug monitoring on a weekly basis, given its drug-drug interaction and great interpersonal variability due to genetic polymorphisms of CYP3A4. Finally, it is important to note that critically ill patients with SARS-CoV-2 infection may suffer from other fungal infections [16] . Like other patients admitted to the ICU, critically ill patients with SARS-CoV-2 can develop candidemia due to prolonged ICU length of hospital stay, invasive medical devices, use of broad-spectrum antibiotics and corticosteroids, etc. More occasionally, though, other fungal infections like Pneumocystis jirovecci or mucormycosis have been described. The authors declare no conflicts of interest. Broad spectrum. Linear and predictable pharmacokinetics. Not influenced by genetic polymorphisms or by diet. Does not need therapeutic drug monitoring. High volume of distribution; high dose in lung. Few side effects. Cyclodextrin-free. Can be used in renal failure, dialysis, and hemodialysis. Table 1 Main advantages of isavuconazole versus voriconazole. Invasive Pulmonary Aspergillosis Associated With Influenza Influenza-associated aspergillosis in critically ill patients Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion Invasive aspergillosis in critically ill patients: Review of definitions and diagnostic approaches. Mycoses Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study Intensive care management of influenza-associated pulmonary aspergillosis Aspergillosis complicating severe coronavirus disease COVID-19-Associated Pulmonary Aspergillosis Confirmed invasive pulmonary aspergillosis and COVID-19: The value of postmortem findings to support antemortem management COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients Detection of invasive pulmonary aspergillosis in COVID-19 with Nondirected BAL Isolation of Aspergillus spp. in respiratory samples of patients with COVID-19 in a Spanish Tertiary Care Hospital Invasive pulmonary aspergillosis complicating COVID-19 in the ICU -A case report COVID-19 associated pulmonary aspergillosis COVID-19-associated invasive pulmonary aspergillosis Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: A retrospective case series Azole-resistant COVID-19-associated pulmonary aspergillosis in an immunocompetent host: A case report Multi-triazole-resistant Aspergillus fumigatus and SARS-CoV-2 co-infection: A lethal combination Fatal disseminated aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus ochraceus COVID-19-associated pulmonary aspergillosis in a Japanese man: A case report SARS-CoV-2 and Aspergillus section Fumigati coinfection in an immunocompetent patient treated with corticosteroids Invasive pulmonary aspergillosis and hyperthermia in an immunocompetent patient with COVID-19 Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ ISHAM consensus criteria for research and clinical guidance Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study A National Strategy to Diagnose Coronavirus Disease 2019-Associated Invasive Fungal Disease in the Intensive Care Unit Update by the GEMICOMED-SEIMC/ REIPI Documento de consenso del GEMICOMED perteneciente a la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) sobre el tratamiento de las infecciones invasoras producidas por Aspergillus Important drug classes associated with potential drug-drug interactions in critically ill patients: highlights for cardiothoracic intensivists Antimicrobial Drug Interactions in the Critically Ill Patients Fungal co-infection in COVID-19 patients: Should we be concerned? Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. medRxiv Clinical and virological data of the first cases of COVID-19 in Europe: a case series Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19 Invasive aspergillosis in patients with severe COVID-19 pneumonia COVID-19-associated pulmonary aspergillosis Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient Recovery of a triazole-resistant Aspergillus fumigatus in respiratory specimen of COVID-19 patient in ICU -A case report